National project paves way for clinical genetic diagnosis

Thousands to benefit from rare disease diagnosis

National project paves way for clinical genetic diagnosis

141217-ddd1.pngDOI: 10.1016/S0140-6736(14)61705-0
Individual genetic diagnoses associated with broad phenotype characteristics catalogued in known Developmental Disorders Genotype-to-Phenotype database genes. The circos-style plot links the genomic location of each gene with some key phenotypes in each child.

The first nationwide project to genetically diagnose rare diseases will pave the way for translating advances in genomics into patient care in the NHS. Deciphering Developmental Disorders (DDD), which is funded by the Wellcome Trust Sanger Institute and the Department of Health and Wellcome Trust through the Health Innovation Challenge Fund, is working with 12,000 families to diagnose their child's developmental disorder, demonstrating the feasibility and value of introducing large-scale sequencing diagnostics into health care.

The project, which will continue into next year, has so far found a diagnosis for nearly a third of the first 1000 families analysed, where previous genetic tests were unable to find the cause. The diagnoses have focused on the 1100 genes that have previously been recognised as a cause of developmental disorders. This success rate will continue to improve as more disease-causing genes are discovered.

"Each of these patient families has been through a long diagnostic odyssey before taking part in the DDD project. For many, we are able to offer the diagnosis they have waited so long for. Sometimes this improves clinical management, but simply knowing the source of the problem can provide families with peace of mind."

Dr Helen Firth, an author from the Department of Clinical Genetics at Addenbrooke's Hospital

Genome-wide microarray and whole exome sequencing is used to identify nearly 80,000 variants in each child, a handful of which potentially hold the genetic key to their disorder. Filtering out benign changes and unrelated findings accurately and efficiently is the major challenge facing researchers. A key step in this process is to compare symptoms identified by clinicians, such as neurodevelopmental delay or abnormal growth, with an in-house database of all known genes associated with developmental disorders.

"This project requires the collaborative efforts of hundreds of NHS staff and researchers. Clinicians managing patients on the frontline, database curators ploughing through the latest research, bioinformaticians developing computational tools and genetics experts interpreting results are all working together towards the common goal of finding answers for these patients."

Dr David FitzPatrick an author from the Medical Research Council's Human Genetics Unit in Edinburgh

Most of the causative genetic changes are new mutations in the affected child that were not inherited from either parent. Where unaffected parents were sequenced as well as the child, researchers saw a 10-fold reduction in the number of variants needing clinical evaluation. This study shows the importance of using parental genetic data, where possible, for the diagnosis of rare disorders.

The DDD study will continue to recruit families until April 2015, and will continue to try to find a genetic diagnosis for all the remaining undiagnosed families. It is hoped that the approach developed in this study will be rapidly incorporated in standard clinical practice to maximise the diagnosis of rare genetic disorders.

"By pulling together 24 regional genetics services and more than 180 clinical geneticists, we've implemented one single exome sequence diagnostic pipeline for children across the country. The project has shown that large-scale genome-wide testing, which brings such enormous benefits to patients and families, is both effective and affordable."

Dr Caroline Wright, lead author and Programme Manager for the Deciphering Developmental Disorders project

The research is published in The Lancet.

Notes to Editors
Publications
  • Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data.

    Wright CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF et al.

    Lancet (London, England) 2015;385;9975;1305-14

Funding

The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health and the Wellcome Trust Sanger Institute [grant number WT098051].

Participating Centres

Wellcome Trust Sanger Institute, University of Oxford, University of Edinburgh, Cambridge University Hospitals Foundation Trust and all NHS regional genetics services in the UK and Republic of Ireland.

Selected Websites
Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Low doses of radiation promote cancer-capable cells
New research in mice helps to understand the risks around exposure to low doses of radiation, such as CT scans and x-rays
Chan Zuckerberg Initiative boosts Human Cell Atlas research at the Sanger Institute
Seed Networks projects will focus on specific tissues, such as the thymus, lung, liver, kidney and immune system
Widely-available antibiotics could be used in the treatment of ‘superbug’ MRSA
Genomic analysis shows that a significant number of strains are susceptible to penicillin combined with clavulanic acid